ºÚÁÏÃÅ

ºÚÁÏÃÅ announces four new agreements with top pharmaceutical companies, driven by ºÚÁÏÃÅ’ proven leadership and expertise in digital biomarker development and the strength of its comprehensive, device-and location-agnostic clinical trial solution.

Digital measures hold immense promise for revolutionizing drug development and advancing our understanding of treatment efficacy. Yet despite their transformative potential, their full utilization remains hindered by standardization hurdles, regulatory ambiguity, and limited awareness among patients and healthcare providers. ºÚÁÏÃÅ and HealthXL recently set out to analyze the state of digital measures in drug development.

ºÚÁÏÃÅ Expands Access to Care and Streamlines Workflows with Integrated On-Demand In-Home Services Ecosystem. Nursing, phlebotomy, infusion, durable medical equipment, imaging and other ancillary services easily ordered from curated network of service partners via ºÚÁÏÃÅ platform.

ºÚÁÏÃÅ, a leading global technology-enabled care delivery company, announced today that it has forged a new agreement with Nascentia Health, which offers a complete range of care management and insurance services that helps patients in Central New York receive the care they need at home.

An industry report released today forecasts that digital endpoints will see broader adoption in supporting pharmaceutical and life science label claims in the years ahead—but only after industry-wide, pre-competitive collaboration aimed at standardization and proactive sharing of data around clinically validated patient-centric outcomes.

Hear how healthcare leaders are successfully implementing and scaling care-at-home strategies.

ºÚÁÏÃÅ in partnership with Becker's Healthcare collected insights and feedback from various health system across the nation to understand the current state of home and site-agnostic care.

ºÚÁÏÃÅ, a leading global technology-enabled care delivery company, announced today the release of its expanded Digital Clinical Trials solution within the ºÚÁÏÃÅ platform for biopharma and other life sciences companies.

Over the past several years, more and more healthcare systems have deployed remote patient management programs to expand access to care. By 2025, it is estimated that remote patient management solutions will reach over 70 million patients in the U.S. As these programs scale up, how do we ensure they continue to deliver real value to providers as well as patients?